Exercise and Time of Day in Type 2 Diabetes

Description

The overall purpose of the study is to test the effect of Noom on exercise and diet advice in adults with type 2 diabetes. The overarching hypothesis is that the use of Noom may promote better dietary adherence during an exercise program, thereby promoting greater weight loss and cardiometabolic health compared to lifestyle advice only. In particular, the investigators anticipate that changes in metabolic and vascular insulin sensitivity will correlate with glycemic control and blood pressure changes.

Conditions

Diabetes Mellitus, Type 2, Metabolic Syndrome

Talk to us

Study Overview

On this page

Study Details

Study overview

The overall purpose of the study is to test the effect of Noom on exercise and diet advice in adults with type 2 diabetes. The overarching hypothesis is that the use of Noom may promote better dietary adherence during an exercise program, thereby promoting greater weight loss and cardiometabolic health compared to lifestyle advice only. In particular, the investigators anticipate that changes in metabolic and vascular insulin sensitivity will correlate with glycemic control and blood pressure changes.

Exercise Time of Day for Cardiometabolic Health in Type 2 Diabetes

Exercise and Time of Day in Type 2 Diabetes

Condition
Diabetes Mellitus, Type 2
Intervention / Treatment

-

Contacts and Locations

New Brunswick

New Jersey Institute for Food, Nutrition, and Health, New Brunswick, New Jersey, United States, 08901

New Brunswick

Robert Wood Johnson University Hospital Clinical Research Center, New Brunswick, New Jersey, United States, 08901

New Brunswick

Rutgers University Loree Gymnasium, New Brunswick, New Jersey, United States, 08901

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Male or female \>30 and \<70 years old.
  • * Has a body mass index \>28 and \<45 kg/m2.
  • * Previously diagnosed with T2DM.
  • * Subjects currently taking medications that affect heart rate and rhythm (i.e. Ca++ channel blockers, nitrates, alpha- or beta-blockers).
  • * Morbidly obese patients (BMI \>46 kg/m2) and overweight/lean patients (BMI \<27 kg/m2)
  • * Evidence of type 1 diabetes and diabetics requiring insulin therapy
  • * Subjects who have not been weight stable (\>2 kg weight change in past 3 months)
  • * Subjects who have been recently active (\>30 min of moderate/high intensity exercise, 2 times/week).
  • * Subjects who are smokers or who have quit smoking \<1 years ago
  • * Subjects with abnormal estimated glomerular filtration rate (eGFR).
  • * Hypertriglyceridemic (\>400 mg/dl) and hypercholesterolemic (\>260 mg/dl) subjects
  • * Hypertensive (\>160/100 mmHg)
  • * Subjects with a history of significant metabolic, cardiac, congestive heart failure, cerebrovascular, hematological, pulmonary, gastrointestinal, liver, renal, or endocrine disease or cancer that in the investigator's opinion would interfere with or alter the outcome measures or impact subject safety.
  • * Pregnant (as evidenced by positive urine pregnancy test) or nursing women
  • * Subjects with contraindications to participation in an exercise training program
  • * Currently taking active weight suppression medication (e.g. phentermine,orlistat, lorcaserin, naltrexone-bupropion in combination, liraglutide, benzephetamine, diethylpropion, phendimetrazine)
  • * Known hypersensitivity to perflutren (contained in Definity)

Ages Eligible for Study

30 Years to 70 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Rutgers, The State University of New Jersey,

Steven K Malin, PhD, PRINCIPAL_INVESTIGATOR, Rutgers University - New Brunswick

Study Record Dates

2025-02-28